相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
Philip Saunders et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
A. Schayowitz et al.
BRITISH JOURNAL OF CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
Update on radiation-based therapies for prostate cancer
Young Kwok et al.
CURRENT OPINION IN ONCOLOGY (2010)
Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
Yoko Nagata et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
Ankur Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer
Taro Matsuzaki et al.
CANCER SCIENCE (2009)
Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
James D. Murphy et al.
CLINICAL CANCER RESEARCH (2009)
Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts
Andrea S. Fung et al.
CLINICAL CANCER RESEARCH (2009)
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Karen E. Knudsen et al.
CLINICAL CANCER RESEARCH (2009)
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Todd M. Morgan et al.
CURRENT CANCER DRUG TARGETS (2009)
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
Kanishka Sircar et al.
JOURNAL OF PATHOLOGY (2009)
Regulation of Protein Synthesis by Ionizing Radiation
Steve Braunstein et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Oleksandr Ekshyyan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Mechanisms mediating androgen receptor reactivation after castration
Xin Yuan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?
Eric A. Klein et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Targeting the androgen receptor pathway in prostate cancer
Yu Chen et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
Todd M. Morgan et al.
PROSTATE (2008)
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
Nasredine Aissat et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
TOR signaling is a determinant of cell survival in response to DNA damage
Changxian Shen et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option
Gregory W. Allen et al.
CANCER (2007)
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline
D. Andrew Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
Mary-Ellen Taplin
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
Weisheng Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells
Carolyn Cao et al.
CANCER RESEARCH (2006)
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins
Youyuan Xu et al.
CANCER RESEARCH (2006)
Expression of mTOR signaling pathway markers in prostate cancer progression
Celeste L. Kremer et al.
PROSTATE (2006)
Combined androgen blockade: An update
L Klotz
UROLOGIC CLINICS OF NORTH AMERICA (2006)
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
LC Wu et al.
CANCER RESEARCH (2005)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
N Gao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Molecular characterization of human prostate carcinoma cell lines
A van Bokhoven et al.
PROSTATE (2003)
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M Bolla et al.
LANCET (2002)
Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling
S Mousses et al.
ONCOGENE (2001)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo et al.
ONCOGENE (2000)
分享论文
